LyrArc Article Gist
The German company Bayer faces an unusual situation trying to settle all lawsuits for Roundup weed killer that claim it causes cancer. It is settling lawsuits even while the product remains on the shelves at retailers. Bayer is not allowed to put warning labels by the EPA and regulators on Roundup that is on the shelves, because the EPA says glyphosate is not a chemical that causes cancer.  Bayer has already lost in three jury trials and faces the unusual predicament of not being able to remove the ingredient or put a warning label to avert future litigation.

Bayer had lost a third of its stock value as the legal situation worsened. Investors are very critical of the acquisition of Monsanto for $63 billion by CEO Mr. Baumann in June 2018. Monsanto sold Roundup and this is how it ended up in Bayer's products with sales of $200 million. The legal settlements plan is 50 times this. $8 billion for current lawsuits and $2 billion for future lawsuits. And future lawsuits are unpredictable creating uncertainty for Bayer. Investors question whether such an acquisition was a good idea in the first place.